
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May 2024

Commission File Number 1-14840

AMDOCS LIMITED

**Hirzel House, Smith Street,
St. Peter Port, Island of Guernsey, GY1 2NG
Amdocs, Inc.
625 Maryville Centre Drive, Suite 200, Saint Louis, Missouri 63141
(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

FORM 20-F

FORM 40-F

On May 8, 2024 Amdocs Limited (“Amdocs”) issued a press release announcing financial results for the quarter ended March 31, 2024. A copy of the press release and the accompanying presentation are furnished as Exhibits 99.1 and 99.2 to this Report of Foreign Private Issuer on Form 6-K.

The information in this Form 6-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

EXHIBIT INDEX

<u>EXHIBIT NO.</u>	<u>DESCRIPTION</u>
99.1	Amdocs Limited Press Release Announcing Q2 Earnings, dated May 8, 2024
99.2	Fiscal Q2 2024 Earnings Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMDOCS LIMITED

By: /s/ Matthew E. Smith
Matthew E. Smith
Secretary and Authorized Signatory

Date: May 8, 2024



Amdocs Limited Reports Second Quarter Fiscal 2024 Results

*Record Quarterly Revenue of \$1.25 Billion, up 1.8% YoY as Reported and 2% YoY in Constant Currency⁽¹⁾
Record 12-Month Backlog of \$4.23 Billion, up ~3% YoY*

*Updates Fiscal 2024 Outlook:
Expects Revenue Growth of 1.6%-3.6% YoY as Reported and 1.7%-3.7% YoY in Constant Currency⁽¹⁾
On-track to Deliver Accelerated Profitability in Fiscal 2024
Expects GAAP Diluted EPS Growth of 7.0%-13.0% and
Non-GAAP Diluted EPS Growth of 7.0%-11.0%*

Second Quarter Fiscal 2024 Highlights

(All comparisons are against the prior year)

- Record revenue of \$1,246 million, up 1.8% as reported and up 2.0% in constant currency⁽¹⁾; revenue was slightly above the midpoint of \$1,225-\$1,265 million guidance range and includes an unfavorable impact from foreign currency movements of approximately \$2 million relative to the second quarter of fiscal 2023
- GAAP diluted EPS of \$1.01, including a restructuring charge of 24 cents per share, without which GAAP diluted EPS would have been at the midpoint of the guidance range of \$1.21-\$1.29
- Non-GAAP diluted EPS of \$1.56, at the midpoint of the guidance range of \$1.53-\$1.59
- GAAP operating income of \$156 million; GAAP operating margin of 12.5%, down 240 basis points as compared to last year's second fiscal quarter and down 230 basis points sequentially, primarily reflecting restructuring charges of \$33 million recorded in the second fiscal quarter

- (1) Revenue on a constant currency basis assumes exchange rates in the current period were unchanged from the prior period
 (2) Please refer to the Selected Financial Metrics tables below (figures may not sum because of rounding)
 (3) Expected total shareholder return assumes Non-GAAP EPS growth plus dividend yield

- Non-GAAP operating income of \$229 million; non-GAAP operating margin of 18.4%, up 60 basis points as compared to last year's second fiscal quarter and up 30 basis points sequentially, reflecting a continued focus on operational excellence
- Managed services revenue of \$720 million, equivalent to approximately 58% of total revenue
- Free cash flow of \$113 million, comprised of cash flow from operations of \$133 million, less \$20 million in net capital expenditures and other⁽²⁾, including \$7 million of restructuring payments
- Repurchased \$115 million of ordinary shares during the second fiscal quarter
- Record twelve-month backlog of \$4.23 billion, up approximately 3% as compared to last year's second fiscal quarter and up approximately \$20 million sequentially

JERSEY CITY, NJ – May 8, 2024 – Amdocs Limited (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today reported operating results for the three months ended March 31, 2024.

“I am pleased to report solid results for the second fiscal quarter, including record revenue, improved profitability, and healthy sales momentum as we delivered the market-leading innovation our customers need to support cloud migration, 5G monetization, digital modernization, and network automation. During Q2, we strengthened our relationships at several North American operators, and expanded our international footprint with several major network and digital modernizations wins, including Colt in the UK, a large Southeast Asian operator, and J:COM in Japan. I am very happy to report that we just signed a significant 5-year deal at AT&T, which expands our activities in the cloud domain, as well as extends our engagement with AT&T in the consumer domain,” said Shuky Sheffer, president and chief executive officer of Amdocs Management Limited.

“Second quarter operating profitability improved significantly on a sequential and year-over-year basis, reflecting our long-term commitment to operational excellence and the ongoing adoption of automation, artificial intelligence, and other sophisticated tools to drive internal efficiency. Among other highlights, we expanded our long-standing managed services relationship with Rogers in Canada to support its recent merger with Shaw under an

extended multi-year agreement, and we expanded and extended our multi-year partnership with a major Southeast Asian service provider to include full cloud managed services and operations,” said Tamar Rapaport-Dagim, chief financial officer & chief operating officer of Amdocs Management Limited.

Sheffer concluded, “We continue to operate within a challenging environment of macro uncertainty and industry pressure. As the preferred technology partner for modernization, we continue to see healthy market demand for Amdocs’ innovative products and services around our strategic pillars, supporting double-digit revenue growth in cloud. I am also encouraged by our progress advancing multiple Gen AI development engagements in collaboration with key partners such as Nvidia, Microsoft and AWS, and several flagship customers. Looking to the fiscal second half, we expect sequential revenue growth based on our record 12-month backlog and an attractive pipeline of opportunities, albeit at a more moderate rate than we initially anticipated. Altogether, we now expect constant currency⁽¹⁾ revenue growth of 1.7% to 3.7% year-over-year in fiscal 2024. Moreover, our accelerated profitability improvement is tracking in line with our initial targets, and we are positioned to deliver double-digit expected total shareholder returns⁽³⁾ for the fourth year running.”

Revenue

(All comparisons are against the prior year period)

	In millions	
	Three months ended	
	March 31, 2024	
	Actual	Guidance
Revenue	\$1,246	\$1,225 - \$1,265
Revenue Growth, as reported	1.8%	
Revenue Growth, constant currency (1)	2.0%	

- Revenue for the second fiscal quarter of 2024 was slightly above the midpoint of Amdocs' guidance, and includes immaterial impact from foreign currency movement compared to our guidance assumptions
- Revenue for the second fiscal quarter includes an impact from foreign currency movements of approximately \$2 million relative to the first quarter of fiscal 2024

Net Income and Earnings Per Share

	<u>In thousands, except per share data</u>	
	<u>Three months ended</u>	
	<u>March 31,</u>	
	<u>2024</u>	<u>2023</u>
GAAP Measures		
Net Income	\$ 119,425	\$ 150,309
Net Income attributable to Amdocs Limited	\$ 118,502	\$ 149,603
Diluted earnings per share	\$ 1.01	\$ 1.23
Non-GAAP Measures		
Non-GAAP Net Income	\$ 183,620	\$ 179,298
Non-GAAP Net Income attributable to Amdocs Limited	\$ 182,697	\$ 178,592
Non-GAAP Diluted earnings per share	\$ 1.56	\$ 1.47

- Non-GAAP net income excludes amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition related liabilities measured at fair value, equity-based compensation expenses, and other, net of related tax effects, in all the periods presented, and in the three months ended March 31, 2024, also excludes restructuring charges net of related tax effects

For further details of the reconciliation of selected financial metrics from GAAP to Non-GAAP, please refer to the tables below.

Capital Allocation

- **Quarterly Cash Dividend Program:** On May 8, 2024, the Board approved the Company's next quarterly cash dividend payment of \$0.479 per share, and set June 28, 2024 as the record date for determining the shareholders entitled to receive the dividend, which will be payable on July 26, 2024

- **Share Repurchase Activity:** Repurchased \$115 million of ordinary shares during the second quarter of fiscal 2024

Twelve-month Backlog

Twelve-month backlog was a record \$4.23 billion at the end of the second quarter of fiscal 2024, up approximately 3% as compared to last year's second fiscal quarter. Twelve-month backlog includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities.

Third Quarter Fiscal 2024 Outlook

	In millions, expect per share data
	Q3 - 2024
Revenue	\$ 1,235-\$1,275
GAAP Diluted earnings per share	\$ 1.24-\$1.32
Non-GAAP Diluted earnings per share	\$ 1.57-\$1.63

- Third quarter revenue guidance assumes immaterial sequential impact from foreign currency fluctuations as compared to the second quarter of fiscal 2024
- Third quarter non-GAAP diluted EPS guidance excludes equity-based compensation expense of approximately \$0.18-\$0.20 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately \$0.11 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects
- GAAP diluted EPS guidance does not include the impact of future expected restructuring charges

Full Year Fiscal 2024 Outlook

	FY 2024 - Year-over - Year growth	
	Current guidance	Previous guidance
Revenue Growth, as reported	1.6%-3.6%	1.1%-5.1%
Revenue Growth, constant currency (1)	1.7%-3.7%	1.2%-5.2%
GAAP Diluted earnings per share	7.0%-13.0%	13.0%-19.5%
Non-GAAP Diluted earnings per share	7.0%-11.0%	8.0%-12.0%

	FY 2024, in millions	
	Current guidance	Previous guidance
Free Cash Flow (2)	\$ 700	\$ 750

- Full year fiscal 2024 revenue guidance incorporates an expected unfavorable impact from foreign currency fluctuations of approximately 0.1% year-over-year, consistent with our previous assumption
- Non-GAAP diluted earnings per share growth excludes equity-based compensation expense of approximately \$0.73-\$0.77 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately \$0.46 per share, restructuring charges of \$0.24 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects
- GAAP diluted EPS guidance does not include the impact of future expected restructuring charges
- Non-GAAP operating margin is anticipated to be within a range of 18.1% to 18.7% for the full year fiscal 2024
- Non-GAAP operating margin is comprised of GAAP operating margin, excluding amortization on purchased intangible assets and other, equity-based compensation expense, restructuring charges, and changes in certain acquisitions related liabilities measured at fair value
- Non-GAAP effective tax rate is anticipated to be within a range of 13% to 17% for the full year fiscal 2024
- Free cash flow⁽²⁾ is comprised of cash flow from operations, less net capital expenditures and other, and excludes payments related to restructuring charges

The forward looking statements regarding our third fiscal quarter 2024 and full year fiscal 2024 guidance take into consideration the Company's current expectations regarding macro and industry specific risks and various uncertainties and certain assumptions that we will discuss on our earnings conference call. However, we note that market dynamics

continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from certain geopolitical events (including the recent attacks in Israel and evolving conflict), the current inflationary environment, global or regional events, such as the COVID-19 pandemic and the prevailing level of macro-economic, business and operational uncertainty, which have created, and continue to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities.

Conference Call and Earnings Webcast Presentation Details

Amdocs will host a conference call and earnings webcast presentation on May 8, 2024 at 5:00 p.m. Eastern Time to discuss the Company's second quarter of fiscal 2024 results. To participate in the call, please register [here](#) to receive the dial-in numbers and unique access PIN. The conference call and webcast will also be carried live on the Internet and may be accessed via the Amdocs website at <https://investors.amdocs.com>. Presentation slides will be available shortly before the webcast.

Non-GAAP Financial Measures This release includes non-GAAP diluted earnings per share and other non-GAAP financial measures, including free cash flow, revenue on a constant currency⁽¹⁾ basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth. These other non-GAAP measures exclude the following items:

- amortization of purchased intangible assets and other acquisition-related costs;
- changes in certain acquisition-related liabilities measured at fair value;
- restructuring and unusual charges or benefits;
- equity-based compensation expense;
- other; and
- tax effects related to the above.

Free cash flow equals cash generated by operating activities less net capital expenditures and other. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures.

Amdocs believes that the presentation of non-GAAP diluted earnings per share and other financial measures, including free cash flow⁽²⁾, revenue on a constant currency⁽¹⁾ basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business.

For its internal budgeting process and in monitoring the results of the business, Amdocs' management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition-related liabilities measured at fair value, restructuring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs' management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items.

Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below.

Supporting Resources

- Keep up with Amdocs news by visiting the Company's [website](#)
- Subscribe to Amdocs' [RSS Feed](#) and follow us on [Twitter](#), [Facebook](#), [LinkedIn](#) and [YouTube](#)

About Amdocs

Amdocs helps those who build the future to make it amazing. With our market-leading portfolio of software products and services, we unlock our customers' innovative potential, empowering them to provide next-generation communication and media experiences for both the individual end user and large enterprise customers. Our approximately 29,000 employees around the globe are here to accelerate service providers' migration to the cloud, enable them to differentiate in the 5G era, and digitalize and automate their operations. Listed on the NASDAQ Global Select Market, Amdocs had revenue of \$4.89 billion in fiscal 2023.

For more information, visit Amdocs at www.amdocs.com.

This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other global or regional events such as the October 7, 2023 attacks in Israel and evolving conflict and the COVID-19 pandemic, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2023 filed on December 13, 2023 and our Form 6-K furnished for the first quarter of fiscal 2024 on February 20, 2024.

Contact:

Matthew Smith

Head of Investor Relations

Amdocs 314-212-8328

E-mail: dox_info@amdocs.com

AMDOCS LIMITED
Consolidated Statements of Income
(In thousands, except per share data)

	Three months ended March 31,		Six months ended March 31,	
	2024	2023	2024	2023
Revenue	\$1,245,849	\$1,223,304	\$2,491,048	\$2,409,024
Operating expenses:				
Cost of revenue	801,996	795,485	1,614,740	1,552,334
Research and development	91,154	89,274	180,361	185,000
Selling, general and administrative	147,609	143,328	290,113	286,550
Amortization of purchased intangible assets and other	16,198	12,940	32,608	28,253
Restructuring charges	33,160	—	33,160	24,536
	<u>1,090,117</u>	<u>1,041,027</u>	<u>2,150,982</u>	<u>2,076,673</u>
Operating income	155,732	182,277	340,066	332,351
Interest and other expense, net	(11,650)	(2,938)	(21,428)	(7,901)
Income before income taxes	144,082	179,339	318,638	324,450
Income taxes	24,657	29,030	50,491	44,269
Net income	<u>\$ 119,425</u>	<u>\$ 150,309</u>	<u>\$ 268,147</u>	<u>\$ 280,181</u>
Net income attributable to noncontrolling interests	923	706	1,680	911
Net income attributable to Amdocs Limited	<u>\$ 118,502</u>	<u>\$ 149,603</u>	<u>\$ 266,467</u>	<u>\$ 279,270</u>
Basic earnings per share attributable to Amdocs Limited	\$ 1.02	\$ 1.24	\$ 2.28	\$ 2.32
Diluted earnings per share attributable to Amdocs Limited	\$ 1.01	\$ 1.23	\$ 2.27	\$ 2.30
Cash dividends declared per ordinary share	\$ 0.479	\$ 0.435	\$ 0.914	\$ 0.830
Basic weighted average number of shares outstanding	116,404	120,516	116,623	120,585
Diluted weighted average number of shares outstanding	<u>117,125</u>	<u>121,359</u>	<u>117,331</u>	<u>121,430</u>

AMDOCS LIMITED
Selected Financial Metrics
(In thousands, except per share data)

	Three months ended March 31,		Six months ended March 31,	
	2024	2023	2024	2023
Revenue	\$1,245,849	\$1,223,304	\$2,491,048	\$2,409,024
Non-GAAP operating income	229,434	217,737	454,675	427,275
Non-GAAP net income	183,620	179,298	367,453	355,840
Non-GAAP net income attributable to Amdocs Limited	182,697	178,592	365,773	354,929
Non-GAAP diluted earnings per share	\$ 1.56	\$ 1.47	\$ 3.12	\$ 2.92
Diluted weighted average number of shares outstanding	117,125	121,359	117,331	121,430

Free Cash Flows
(In thousands)

	Three months ended March 31,		Six months ended March 31,	
	2024	2023	2024	2023
Net Cash Provided by Operating Activities	\$132,657	\$294,476	\$315,044	\$377,702
Purchases of property and equipment, net (a)	(19,603)	(35,119)	(63,346)	(68,822)
Free Cash Flow	\$113,054	\$259,357	\$251,698	\$308,880

- (a) The amounts under "Purchase of property and equipment, net", include immaterial proceeds from sale of property and equipment for the six months ended March 31, 2024, and \$255 for the six months ended March 31, 2023.

AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)

	Three Months Ended March 31, 2024							Non-GAAP
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Restructuring charges	Other	Tax effect	
Operating expenses:								
Cost of revenue	\$ 801,996	\$ —	\$ (13,248)	\$ 2,001	\$ —	\$ —	\$ —	\$ 790,749
Research and development	91,154		(2,256)					88,898
Selling, general and administrative	147,609		(10,841)					136,768
Amortization of purchased intangible assets and other	16,198	(16,198)						—
Restructuring charges	33,160				(33,160)			—
Total operating expenses	1,090,117	(16,198)	(26,345)	2,001	(33,160)	—	—	1,016,415
Operating income	155,732	16,198	26,345	(2,001)	33,160	—	—	229,434
Interest and other expense, net	(11,650)					4,004		(7,646)
Income taxes	24,657						13,511	38,168
Net income	119,425	16,198	26,345	(2,001)	33,160	4,004	(13,511)	183,620
Net income attributable to noncontrolling interests	923							923
Net income attributable to Amdocs Limited	\$ 118,502	\$ 16,198	\$ 26,345	\$ (2,001)	\$ 33,160	\$ 4,004	\$(13,511)	\$ 182,697

	Three Months Ended March 31, 2023						Non-GAAP
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Tax effect		
Operating expenses:							
Cost of revenue	\$ 795,485	\$ —	\$ (10,061)	\$ (1,159)	\$ —		\$ 784,265
Research and development	89,274		(1,703)				87,571
Selling, general and administrative	143,328		(9,597)				133,731
Amortization of purchased intangible assets and other	12,940	(12,940)					—
Total operating expenses	1,041,027	(12,940)	(21,361)	(1,159)	—		1,005,567
Operating income	182,277	12,940	21,361	1,159	—		217,737
Interest and other expense, net	(2,938)						(2,938)
Income taxes	29,030				6,471		35,501
Net income	150,309	12,940	21,361	1,159	(6,471)		179,298
Net income attributable to noncontrolling interests	706						706
Net income attributable to Amdocs Limited	\$ 149,603	\$ 12,940	\$ 21,361	\$ 1,159	\$(6,471)		\$ 178,592

AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)

	Six Months Ended March 31, 2024							
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Restructuring charges	Other	Tax effect	Non-GAAP
Operating expenses:								
Cost of revenue	\$ 1,614,740	\$ —	\$ (26,775)	\$ 3,584	\$ —	\$ —	\$ —	\$ 1,591,549
Research and development	180,361		(4,123)					176,238
Selling, general and administrative	290,113		(21,527)					268,586
Amortization of purchased intangible assets and other	32,608	(32,608)						—
Restructuring charges	33,160				(33,160)			—
Total operating expenses	2,150,982	(32,608)	(52,425)	3,584	(33,160)		—	2,036,373
Operating income	340,066	32,608	52,425	(3,584)	33,160		—	454,675
Interest and other expense, net	(21,428)					5,538		(15,890)
Income taxes	50,491						20,841	71,332
Net income	268,147	32,608	52,425	(3,584)	33,160	5,538	(20,841)	367,453
Net income attributable to noncontrolling interests	1,680							1,680
Net income attributable to Amdocs Limited	\$ 266,467	\$ 32,608	\$ 52,425	\$ (3,584)	\$ 33,160	\$ 5,538	\$ (20,841)	\$ 365,773

	Six Months Ended March 31, 2023							
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Restructuring charges	Tax effect	Non-GAAP	
Operating expenses:								
Cost of revenue	\$ 1,552,334	\$ —	\$ (18,716)	\$ (1,284)	\$ —	\$ —	\$ 1,532,334	
Research and development	185,000		(3,187)				181,813	
Selling, general and administrative	286,550		(18,948)				267,602	
Amortization of purchased intangible assets and other	28,253	(28,253)					—	
Restructuring charges	24,536				(24,536)		—	
Total operating expenses	2,076,673	(28,253)	(40,851)	(1,284)	(24,536)	—	1,981,749	
Operating income	332,351	28,253	40,851	1,284	24,536	—	427,275	
Interest and other expense, net	(7,901)						(7,901)	
Income taxes	44,269					19,265	63,534	
Net income	280,181	28,253	40,851	1,284	24,536	(19,265)	355,840	
Net income attributable to noncontrolling interests	911						911	
Net income attributable to Amdocs Limited	\$ 279,270	\$ 28,253	\$ 40,851	\$ 1,284	\$ 24,536	\$ (19,265)	\$ 354,929	

AMDOCS LIMITED
Condensed Consolidated Balance Sheets
(In thousands)

	As of	
	March 31, 2024	September 30, 2023
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 342,915	\$ 520,080
Short-term interest-bearing investments	201,441	222,451
Accounts receivable, net, including unbilled of \$329,753 and \$211,498, respectively	1,039,440	944,477
Prepaid expenses and other current assets	223,180	224,622
Total current assets	1,806,976	1,911,630
Property and equipment, net	766,123	790,923
Lease assets	162,745	160,938
Goodwill and other intangible assets, net	3,023,854	2,930,580
Other noncurrent assets	644,946	631,582
Total assets	\$6,404,644	\$ 6,425,653
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities		
Accounts payable, accruals and other	\$1,202,517	\$ 1,142,781
Lease liabilities	39,514	39,960
Deferred revenue	127,441	170,634
Total current liabilities	1,369,472	1,353,375
Lease liabilities	117,777	121,654
Long-term debt, net of unamortized debt issuance costs	645,991	645,696
Other noncurrent liabilities	683,883	737,996
Total Amdocs Limited Shareholders' equity	3,544,412	3,523,759
Noncontrolling interests	43,109	43,173
Total equity	3,587,521	3,566,932
Total liabilities and equity	\$6,404,644	\$ 6,425,653

AMDOCS LIMITED
Consolidated Statements of Cash Flows
(In thousands)

	Six months ended	
	March 31,	
	2024	2023
Cash Flow from Operating Activities:		
Net income	\$ 268,147	\$ 280,181
Reconciliation of net income to net cash provided by operating activities:		
Depreciation, amortization and impairment	97,851	103,086
Amortization of debt issuance cost	296	287
Equity-based compensation expense	52,425	40,851
Deferred income taxes	559	(27,357)
Loss from short-term interest-bearing investments	4,640	1,625
Net changes in operating assets and liabilities, net of amounts acquired:		
Accounts receivable, net	(71,288)	(53,485)
Prepaid expenses and other current assets	19,305	(20,416)
Other noncurrent assets	(14,493)	(245)
Lease assets and liabilities, net	(6,130)	(3,928)
Accounts payable, accrued expenses and accrued personnel	70,073	(38,602)
Deferred revenue	(48,528)	81,959
Income taxes payable, net	(62,228)	(11,245)
Other noncurrent liabilities	4,415	24,991
Net cash provided by operating activities	<u>315,044</u>	<u>377,702</u>
Cash Flow from Investing Activities:		
Purchase of property and equipment, net (a)	(63,346)	(68,822)
Proceeds from sale of short-term interest-bearing investments	31,141	10,360
Purchase of short-term interest-bearing investments	(9,061)	—
Net cash paid for business acquisitions	(87,129)	—
Other	(391)	(2,593)
Net cash used in investing activities	<u>(128,786)</u>	<u>(61,055)</u>
Cash Flow from Financing Activities:		
Repurchase of shares	(273,941)	(205,637)
Proceeds from employee stock option exercises	16,061	34,840
Payments of dividends	(101,736)	(95,370)
Distribution to noncontrolling interests	(1,744)	—
Payment of contingent consideration from a business acquisition	(2,063)	(453)
Net cash used in financing activities	<u>(363,423)</u>	<u>(266,620)</u>
Net (decrease) increase in cash and cash equivalents	(177,165)	50,027
Cash and cash equivalents at beginning of period	520,080	573,377
Cash and cash equivalents at end of period	<u>\$ 342,915</u>	<u>\$ 623,404</u>

AMDOCS LIMITED
Supplementary Information
(In millions)

	Three months ended				
	March 31, 2024	December 31, 2023	September 30, 2023	June 30, 2023	March 31, 2023
North America	\$ 823.2	\$ 838.1	\$ 834.4	\$ 830.9	\$ 829.0
Europe	184.8	181.4	175.5	187.3	171.7
Rest of the World	237.8	225.7	232.6	217.8	222.6
Total Revenue	<u>\$1,245.8</u>	<u>\$ 1,245.2</u>	<u>\$ 1,242.6</u>	<u>\$1,236.0</u>	<u>\$1,223.3</u>

	Three months ended				
	March 31, 2024	December 31, 2023	September 30, 2023	June 30, 2023	March 31, 2023
Managed Services Revenue	\$ 720.3	\$ 722.5	\$ 718.1	\$ 719.8	\$ 718.9

	as of				
	March 31, 2024	December 31, 2023	September 30, 2023	June 30, 2023	March 31, 2023
12-Month Backlog	\$ 4,230	\$ 4,210	\$ 4,150	\$ 4,140	\$ 4,110

###




Amdocs Limited NASDAQ: DOX

Fiscal Q2 2024 Earnings Presentation
May 8, 2024

Shuky Sheffer
President & CEO

Tamar Rapaport-Dagim
CFO & COO



Disclaimer

The information contained herein in this presentation or delivered or to be delivered to you during this presentation does not constitute an offer, expressed or implied, or a recommendation to do any transaction in Amdocs Limited securities or in any securities of its affiliates or subsidiaries.

This presentation and the comments made by members of Amdocs management in conjunction with it can be found on the Investor Relations section of our website, and, as always, a copy of today's prepared remarks will also be posted immediately following the conclusion of this call. This presentation includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other global or regional events such as the October 7, 2023 attacks in Israel and evolving conflict and the COVID-19 pandemic, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2023 filed on December 13, 2023, and our Form 6-K furnished for the first quarter of fiscal 2024 on February 20, 2024.

This presentation includes non-GAAP financial measures, including non-GAAP operating margin, free cash flow, revenue on a constant currency basis, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited, and non-GAAP earnings per share. Free cash flow equals cash generated by operating activities less net capital expenditures and other. While in prior years Amdocs used normalized free cash flow, a measure of our operating performance, is further adjusted to exclude net capital expenditures related to the new campus development, payments for non-recurring and unusual charges (such as capital gains tax to be paid in relation to the divestiture of OpenMarket), and payments of acquisition related liabilities, Amdocs is no longer reporting normalized free cash flow. Normalized free cash flow is not comparable to free cash flow. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures. Please refer to the appendix for a reconciliation of these metrics to the most comparable GAAP provision.

This presentation also includes pro forma metrics which exclude the financial impact of OpenMarket (divested on December 31, 2020) from fiscal year 2021. Please also review the information contained in Amdocs' press release dated May 8, 2024 with respect to earnings for fiscal Q2 2024. The press release contains additional information regarding Amdocs' outlook for fiscal year 2024 and certain non-GAAP metrics and their reconciliations.

Today's speakers



Shuky Sheffer

President & Chief Executive Officer



Tamar Rapaport-Dagim

Chief Financial Officer & Chief Operating Officer

Earnings call agenda

1 Strategy & business performance update

Shuky Sheffer,
President &
Chief Executive Officer

2 Financial review & outlook

Tamar Rapaport-Dagim,
Chief Financial Officer &
Chief Operating Officer

3 Q&A



Shuky Sheffer

President & Chief Executive Officer

Strategy and business performance update

Thanks to our amazing people around the world, we support our customers' journeys

Close to
100%

Managed services
contract renewals

Over
95%

successful
transformations



Q2/24 - record revenue, continued profitable growth & margin improvement

Revenue⁽¹⁾

RECORD

\$1.25B

Up ~2% YoY⁽²⁾

Non-GAAP operating margin⁽³⁾

18.4%

+60bps YoY
+30bps QoQ
driven by our ongoing initiatives to accelerate profitability

Non-GAAP EPS⁽³⁾

\$1.56

At guidance midpoint

12-month backlog

RECORD

\$4.23B

Up ~3% YoY

1. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period

2. Revenue was up 1.8% YoY as reported and up 2.0% YoY in constant currency in Q2/24

3. Non-GAAP. See reconciliation tables in appendix


Second quarter key highlights





Healthy second quarter sales momentum




Healthy momentum in North America:


Significant 5-year deal expanding activities in a new cloud domain; extends consumer domain engagement to 2029 


Secured new modernization awards at T-Mobile 


5-year continuous modernization agreement 

Amdocs B2B platform expanded across their product offerings 

Expanded our customer footprint intentionally

Digital transformation project 

Connectivity and network-related deals  Leading service provider in Southeast Asia

Subscription and content management 



Unparalleled project execution


CatalogONE major upgrade 

Unified BSS and OSS platform 

Postpaid migration of ~55 M subscribers 



Supporting mission-critical operations and customers' strategic moves

Extended and expanded our partnership to full cloud managed services 

Extended and expanded managed services agreement, supporting merger with Shaw 

Extended and expanded managed services agreement, supporting its acquisition of Lumen's EMEA business 



Strategic growth framework

Empower service providers to deliver seamless next-generation services



Cloud



Digital



5G, FWA
and fiber



Network



B2B

Generative AI

Progress in strategic domains – Generative AI



Generative AI Simplify and accelerate adoption of GenAI across the telecom industry



Infusing Amdocs CES with GenAI

Amdocs' flagship CES24 telco-native, GenAI led suite, now equipped with CES Copilot, a set of embedded GenAI assistants, powered by amAlz; soon to be deployed at several customers



10



Gen AI app factory

Introducing new GenAI use cases that address the key business outcomes of the communication industry



Leveraging strategic partners

Extending the capabilities of Amdocs amAlz through growing collaboration with industry leaders

- Accelerating innovation by leveraging Microsoft's Azure OpenAI service
- Achieving production-scale cost, accuracy and latency improvements, leveraging NVIDIA's full-stack AI foundry service
- Integrate AWS Gen AI tools into our amAlz platform to fuel innovation across telco domains

a | **make it amazing**

Progress in strategic domains - cloud



Cloud Accelerate our customers' multi-year journey to the cloud
Continued strong sales momentum, on-track for double-digit revenue growth in FY2024

Selected examples

Business value



Upgrade and migration of Amdocs CES to Oracle Cloud Infrastructure (OCI)

Flexibility and capacity growth, reduced operational costs, and state-of-the-art cloud infrastructure enabling superior services and enhanced security & customer experience



Modernization of Amdocs CES suite

Significant step in Optus' modernization journey

Signed significant 5-year deal with AT&T expanding cloud activities to a new domain. Leverages Amdocs' acquisition of Astadia and its technology capabilities, which supports highly sophisticated cloud migrations



Progress in strategic domains – digital modernization



Digital modernization

Creating **seamless digital experiences** by transforming technology and IT operations for consumer and B2B customers

Selected examples

Business value



Digital transformation

Operational efficiencies, elevate customer experiences, and unlock new monetization opportunities



connectX: Amdocs' SaaS cloud-native platform powered by GenAI

Seamlessly launch a new digital brand on the cloud



Subscription Marketplace for operating companies in Europe

One-stop shop for digital subscriptions providing an extremely aggregated and convenient experience for end users



Subscription Marketplace

Positive demand for our SaaS platforms: connectX, Amdocs' AI-driven SaaS platform, and Amdocs Subscription Marketplace, a SaaS platform delivering OTT and digital services directly to customers

Progress in strategic domains - 5G, FWA and fiber



5G, FWA and Fiber

Next-generation solutions to unlock new revenue monetization opportunities, such as fixed wireless access, fiber and 5G standalone

Selected example

Business value

colt

OSS Inventory consolidation and merger services

Enable seamless integration and enhanced agility to accelerate time-to-market for new services and offerings

Supporting acquisition timelines of Lumen's EMEA business and enhancing service bundling and upsell strategies for greater revenue generation and competitive advantage

Progress in strategic domains - network automation



Network automation

Delivering **dynamic connected** experiences with **real-time, automated** networks

Selected examples

Business value



Helix Service Assurance suite, follows Amdocs' acquisition of TEOCO's service assurance business last year

Transforming fault and performance management, and driving streamlined assurance processes with artificial intelligence and machine learning

Major service provider in Southeast Asia

End-to-end service orchestration

Streamlines service orchestration, unlocks innovative monetization with AI, accelerates deployment, and cuts costs



Go-live of Medium Earth Orbit (MEO) software-enabled satellite system

Deliver connectivity services worldwide, supported by Amdocs' OSS solutions, encompassing Orchestration, Inventory, and Service Assurance systems

Current operating environment



Continued challenging environment of macro uncertainty and industry pressure



Healthy market demand and high win rate for Amdocs' innovative products and services; expect another year of double-digit cloud revenue growth



Strong progress in GenAI use cases, supported by collaborations with Nvidia, Microsoft, AWS, and flagship customers



Expect sequential revenue growth acceleration in fiscal H2, albeit more moderately than initially expected due to slower pipeline conversion

Updating our FY24 outlook

A

Revenue⁽¹⁾

1.7%-3.7%

YoY growth

Expected double-digit cloud revenue growth; expect sequential revenue growth acceleration in fiscal H2, albeit more moderately than initially expected due to slower pipeline conversion

B

Free cash flow⁽³⁾

~\$700 million

Represents a **healthy free cash flow yield^(3,4) of ~7%**

C

Non-GAAP EBIT⁽²⁾

18.1% - 18.7%

% margin

Remain on track to deliver accelerated YoY profitability improvement, operational excellence focus, leveraging automation and AI for enhanced efficiency

D

Non-GAAP EPS⁽²⁾

7%-11%

YoY growth

Positions us to deliver **double-digit expected total shareholder returns⁽⁵⁾** in fiscal 2024

Remain on track to deliver accelerated YoY profitability improvement

1. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period.

2. Non-GAAP. See reconciliation tables in appendix.

3. Excludes restructuring payments.

4. Yield = expected reported free cash flow of \$700M in FY2024 as a percentage of Amdocs' market capitalization as of May 7, 2024.

5. Expected total shareholder return assumes Non-GAAP EPS growth plus dividend yield (based on fiscal year-end closing share price); FY2024E assumed midpoint of pro forma non-GAAP EPS outlook, and dividend yield at a quarterly rate of \$0.479, as of share price on 11/7/2023.



Tamar Rapaport-Dagim

Chief Financial Officer & Chief Operating Officer

Financial review & outlook

Q2 FY2024 Financial Highlights

- Record revenue, +1.8% YoY as reported and +2.0% YoY constant currency⁽¹⁾
- North America revenue down less than 1% YoY, reflecting slower pipeline conversion
- Healthy growth of ~8% YoY in Europe
- Record revenue in Rest of World, up ~7% YoY
- Improved operating profitability, driven by focus on operational excellence, and ongoing adoption of automation, artificial intelligence, and other sophisticated tools.

1. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period.
2. Non-GAAP. See reconciliation tables in appendix.

Q2 2024 Results

Q2 Revenue

\$1,246 million

+1.8% YoY, +2.0% constant currency⁽¹⁾
Slightly above guidance midpoint
(\$1,225M - \$1,265M)

Q2 Non-GAAP⁽²⁾ Operating Margin

18.4%, +60bps YoY

+30 bps QoQ


Q2 GAAP Diluted EPS

\$1.01 including a 24-cent restructuring charge, without which EPS was in line with guidance (\$1.21 - \$1.29)


Q2 Non-GAAP⁽²⁾ Diluted EPS

\$1.56 at midpoint of guidance
(\$1.53 - \$1.59)

Q2 2024 Revenue vs. Guidance \$ Millions



Q2 2024 Revenue by Region \$ Millions



Leading Indicators & Business Model Visibility

12-Month Backlog

~\$4.23B

Record-high as of March 31, 2024
~ **+3%** YoY, **+\$20M** QoQ

Leading Indicator


Roughly 80%

12-month backlog roughly
averages ~80% of forward
12-month revenue

19

Information Security Level 2 – Sensitive. © 2024 – Proprietary &
Confidential Information of Ardox

Record Quarterly 12-Month Backlog in Q2F24 \$ Billions



12-month backlog includes:

- ★ Anticipated revenue related to contracts
- ⚙️ Estimated revenue from **managed services** contracts
- 📄 Letters of intent
- 🔧 **Maintenance**
- 🔄 Estimated **ongoing support** activities

a. | **make.it
amazing**

Leading Indicators & Business Model Visibility

Managed Services

~\$720M


~58% of total revenue in Q2 F2024



managed services contract renewals

Managed Services Revenue: Fiscal Year to Date \$ Billions

Managed services arrangements support business model resiliency with highly recurring revenue streams, multi-year engagements and high renewal rates, and may also include large-scale digital transformation projects



Expanded existing collaboration, signing a multi-year managed services extension agreement



Multi-year agreement to refine inventory operations, bolster agility, and expedite introduction of new services and offerings to market

Major Southeast Asian service provider

Extended and expanded multi-year BSS managed services agreement, including full cloud managed services and operations and managing over 100 multi-domain non-Amdocs apps

Balance Sheet & Cash Flow

- Reported free cash flow⁽¹⁾ of **\$113 million** in Q2 2024, including \$7 million of restructuring payments
- Ample** liquidity to support ongoing business needs while retaining the capacity to fund future strategic growth investments

1. Non-GAAP. See reconciliation tables in appendix
 2. \$650M senior note, maturing June 2030

DSO's

76 days

+2 days YoY and +1 days QoQ
 DSO's may fluctuate from quarter to quarter

The sequential quarter change in unbilled receivables net of deferred revenue was \$70 million in Q2, aggregating the short-term and long-term balances

The net difference between unbilled receivables and deferred revenue fluctuates from quarter to quarter, in line with normal business activities as well as progress on significant multi-year transformation programs we are currently running in North America.

Liquidity: Cash + Credit Facility

\$1.0 billion


Ample liquidity including available \$500M revolving credit facility

Baa1
Moody's

BBB
S&P

Committed to maintaining our Investment grade credit rating

Q2 2024 Free cash flow⁽¹⁾ bridge



Cash, Credit Facility & Debt Position

\$ Millions, as of March 31, 2024




Disciplined Capital Allocation

- ✦ Expects free cash flow⁽¹⁾ (FCF) of **\$700M⁽⁶⁾** in FY2024, equating to more than 90% cash conversion
- ✦ **~7%** free cash flow yield⁽²⁾⁽⁶⁾
- ✦ Expects to return the **majority** of free cash flow to shareholders in FY2024

1. Non-GAAP. See appendix tables for reconciliation of FCF
 2. Yield = expected reported free cash flow of \$700M in FY2024 as a percentage of Amdocs' market capitalization as of May 7, 2024
 3. FCF in FY2020, FY2021 and FY2022 is presented on a normalized basis, which mainly excludes net capital expenditures related to the new campus development; normalized FCF disclosure is not applicable as of FY2023 onward
 4. Refer to <https://investors.amdocs.com/> and earnings reports issued on 11/2/2021 and 11/8/2022 for reconciliation of normalized FCF in FY2020, FY2021 and FY2022
 5. FY2023 excludes \$20M non-recurring restructuring payments
 6. FY2024 excludes non-recurring restructuring payments

Q2 2024 Cash Returned to Shareholders \$ Millions



Board authorized quarterly dividend payment:


47.9 cents

Payable on July 26, 2024, to shareholders on record date of June 28, 2024

Returned **\$376M** to shareholders through share repurchases and dividend in 1H FY2024

~\$0.8B of aggregate share repurchase authorization remaining as of March 31, 2024

FCF: Four-year historical trend and FY2024E outlook ⁽¹⁾⁽³⁾⁽⁴⁾⁽⁵⁾⁽⁶⁾



FY2024 Revenue Growth Outlook

✦ **Expects** FY2024 revenue growth of **1.7%-3.7% YoY** constant currency⁽²⁾


✦ Expects revenue growth of **1.6%-3.6% YoY** as reported, incorporating an unfavorable foreign currency impact of **-0.1% YoY**

✦ Cloud exceeded **20%** of total revenue in FY2023, and is on-track for **double-digit** revenue growth in FY2024E

1. Pro forma metrics exclude the financial impact of OpenMarket (which was divested on December 31, 2020) from fiscal year 2021.
2. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period

Revenue Growth

YoY% Growth Constant Currency⁽²⁾




Quarterly sequential revenue growth to accelerate in H2 FY2024, albeit at a more moderate rate than initially expected due to a slower pace of pipeline conversion

Profitability Improvement On-Track

- On pace to **achieve** accelerated profitability improvement in FY2024
- Non-GAAP operating margin will be **stronger** in H2 FY2024
- Improvement led by ongoing efforts to **optimize** cost structure, and cumulative benefits of **automation, sophisticated tools** and expected **AI-related** benefits

1. Non-GAAP. See reconciliation tables in appendix
 2. Refer to <https://investor.amdocs.com/> and earnings reports issued on 11/8/2018, 11/12/19, 11/10/20, 11/2/2021 and 11/8/2022 for reconciliation of non-GAAP operating margin in FY2018, FY2019, FY2020, FY2021 and FY2022.

Quarterly Non-GAAP⁽¹⁾ Operating Margin: FY2018 – FY2024E⁽²⁾
 \$ Millions



"We are relentlessly focused on improving the company's cost structure and productivity"



FY2024 Non-GAAP EPS Outlook

✦ Expects midpoint of non-GAAP⁽²⁾ EPS growth of **7%-11%** in FY2024E

✦ Targeting **double-digit** expected total shareholder returns⁽³⁾ for the **fourth year** running in FY2024E


1. Pro forma metrics exclude the financial impact of OpenMarket (which was divested on December 31, 2020) from fiscal year 2021.
2. Non-GAAP. See reconciliation tables in appendix.
3. Expected total shareholder return assumes Non-GAAP EPS growth plus dividend yield (based on fiscal year end closing share price): FY2024E assumed 9% midpoint of non-GAAP EPS outlook, and dividend yield based on quarterly rate of \$0.479 as of share price on 11/7/23
4. Refer to <https://investors.amdocs.com/> and earnings reports issued on 11/10/2020, 11/2/2021 and 11/8/2022 for non-GAAP reconciliation in FY2019, FY2020, FY2021 and FY2022

25

Information Security Level 2 - Sensitive. © 2024 - Proprietary & Confidential Information of Amdocs

Total Shareholder Return⁽³⁾⁽⁴⁾

Non-GAAP⁽²⁾ Diluted EPS Growth YoY % + Dividend Yield
FY21 and FY22 non-GAAP EPS growth is presented pro forma⁽¹⁾



*Non-GAAP⁽²⁾ EPS growth of 9.0%, plus ~2.3% dividend yield



Committed to ESG



TM Forum Moonshot Catalyst winner for our AI-based Carbon Footprint Catalog, developed with Vodafone Germany, AWS, Carbon Footprint, and Snowflake




Hosted **'Elevating Women in Gen AI,'** at MWC, a roundtable with visionary women leaders discussing the gender gap in GenAI and exploring collaborative opportunities for women in tech and society



Included in the **S&P Global Sustainability Yearbook 2024**



ECOVADIS: Awarded with a Gold Medal (95th percentile) 4th year running



Q&A

27

a. | make.it
amazing



Appendix

Outlook & Reconciliation Tables



Q3 & FY2024 Outlook

Positioned to deliver **double-digit** expected total shareholder returns for the **fourth** year running

1. Non-GAAP. See reconciliation tables in appendix

2. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period

29

Information Security Level 2 – Sensitive. © 2024 – Proprietary & Confidential Information of Amdocs

Q3 Fiscal 2024 Outlook

Revenue	\$1,235 - \$1,275 million
GAAP EPS	\$1.24 - \$1.32
Non-GAAP ⁽¹⁾ EPS	\$1.57 - \$1.63
Share Count	116 million
Effective Tax Rate Non-GAAP ⁽¹⁾	High-end of annual target range of 13.0% - 17.0%

Full Year Fiscal 2024 Outlook	Updated	Previous
Revenue growth As reported	1.6% - 3.6%	1.1% - 5.1%
Revenue growth Constant currency ⁽²⁾	1.7% - 3.7%	1.2% - 5.2%
GAAP EPS growth	7.0% - 13.0%	13.0% - 19.5%
Non-GAAP ⁽¹⁾ EPS growth	7.0% - 11.0%	8.0% - 12.0%
Operating Margin Non-GAAP ⁽¹⁾	18.1% - 18.7%	18.1% - 18.7%
Effective Tax Rate Non-GAAP ⁽¹⁾	13.0% - 17.0%	13.0% - 17.0%
Free cash flow ⁽¹⁾	\$700 million	\$750 million



Reconciliation Tables

AMDOCS LIMITED Selected Financial Metrics (In thousands, except per share data)

	Three months ended March 31,		Six months ended March 31,	
	2024	2023	2024	2023
Revenue	\$ 1,245,849	\$ 1,223,304	\$ 2,491,048	\$ 2,409,024
Non-GAAP operating income	229,434	217,737	454,675	427,275
Non-GAAP net income	183,620	179,298	367,453	355,840
Non-GAAP net income attributable to Amdocs Limited	182,697	178,592	365,773	354,929
Non-GAAP diluted earnings per share	\$ 1.56	\$ 1.47	\$ 3.12	\$ 2.92
Diluted weighted average number of shares outstanding	117,125	121,359	117,331	121,430

Free Cash Flows (in thousands)

	Three months ended March 31,		Six months ended March 31,	
	2024	2023	2024	2023
Net Cash Provided by Operating Activities	\$ 132,657	\$ 294,476	\$ 315,044	\$ 377,702
Purchases of property and equipment, net (a)	(19,603)	(35,119)	(63,346)	(68,822)
Free Cash Flow	\$ 113,054	\$ 259,357	\$ 251,698	\$ 308,880

(a) The amounts under "Purchase of property and equipment, net", include immaterial proceeds from sale of property and equipment for the six months ended March 31, 2024, and \$255 for the six months ended March 31, 2023.

Reconciliation Tables

AMDOCS LIMITED Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP (In thousands)

	Three Months Ended March 31, 2024						Non-GAAP
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Restructuring charges	Other	
Operating expenses:							
Cost of revenue	\$ 801,994	\$ -	\$(13,245)	\$ 2,001	\$ -	\$ -	\$ 790,749
Research and development	91,154		(2,256)				88,898
Selling, general and administrative	147,609		(10,841)				136,768
Amortization of purchased intangible assets and other	16,198	(16,198)					-
Restructuring charges	33,160			(33,160)			-
Total operating expenses	1,090,117	(16,198)	(26,345)	2,001	(33,160)	-	1,016,415
Operating income	155,732	16,198	26,345	(2,001)	33,160	-	229,434
Interest and other expense, net	(11,650)					4,004	(7,646)
Income taxes	24,657					13,511	38,168
Net income	119,423	16,198	26,345	(2,001)	33,160	4,004	183,625
Net income attributable to noncontrolling interests	923						923
Net income attributable to Amdocs Limited	\$ 118,502	\$ 16,198	\$ 26,345	\$ (2,001)	\$ 33,160	\$ 4,004	\$ 182,697

	Three Months Ended March 31, 2023						Non-GAAP
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Other	Tax effect	
Operating expenses:							
Cost of revenue	\$ 795,485	\$ -	\$(10,061)	\$(1,159)	\$ -	\$ -	\$ 784,265
Research and development	89,274		(1,703)				87,571
Selling, general and administrative	143,328		(9,597)				133,731
Amortization of purchased intangible assets and other	12,940	(12,940)					-
Total operating expenses	1,041,027	(12,940)	(21,361)	(1,159)	-	-	1,005,567
Operating income	182,277	12,940	21,361	1,159	-	-	217,737
Interest and other expense, net	(2,938)						(2,938)
Income taxes	29,030					6,471	35,501
Net income	150,309	12,940	21,361	1,159	-	(6,471)	179,298
Net income attributable to noncontrolling interests	106						106
Net income attributable to Amdocs Limited	\$ 149,603	\$ 12,940	\$ 21,361	\$ 1,159	\$ -	\$ (6,471)	\$ 178,192

Reconciliation Tables

AMDOCS LIMITED Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP (In thousands)

	Six Months Ended March 31, 2024							
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Restructuring charges	Other	Tax effect	Non-GAAP
Operating expenses:								
Cost of revenue	\$ 1,614,740	\$ -	\$ (26,775)	\$ 3,584	\$ -	\$ -	\$ -	\$ 1,591,549
Research and development	180,361		(4,123)					176,238
Selling, general and administrative	290,113		(21,527)					268,586
Amortization of purchased intangible assets and other	32,608	(32,608)						-
Restructuring charges	33,160				(33,160)			-
Total operating expenses	2,150,982	(32,608)	(32,425)	3,584	(33,160)			2,036,373
Operating income	340,066	32,608	32,425	(3,584)	33,160			434,675
Interest and other expense, net	(21,428)					5,538		(15,890)
Income taxes	50,491						20,841	71,332
Net income	268,147	32,608	32,425	(3,584)	33,160	5,538	(20,841)	367,453
Net income attributable to noncontrolling interests	1,680							1,680
Net income attributable to Amdocs Limited	\$ 266,467	\$ 32,608	\$ 32,425	\$ (3,584)	\$ 33,160	\$ 5,538	\$ (20,841)	\$ 365,773

	Six Months Ended March 31, 2023						
	GAAP	Amortization of purchased intangible assets and other	Equity based compensation expense	Changes in certain acquisitions related liabilities measured at fair value	Restructuring charges	Tax effect	Non-GAAP
Operating expenses:							
Cost of revenue	\$ 1,552,334	\$ -	\$ (18,716)	\$ (1,284)	\$ -	\$ -	\$ 1,532,334
Research and development	185,000		(3,187)				181,813
Selling, general and administrative	286,550		(18,948)				267,602
Amortization of purchased intangible assets and other	28,255	(28,255)					-
Restructuring charges	24,536				(24,536)		-
Total operating expenses	2,076,675	(28,255)	(40,851)	(1,284)	(24,536)		1,981,749
Operating income	332,331	28,255	40,851	1,284	24,536		427,273
Interest and other expense, net	(7,901)						(7,901)
Income taxes	44,269					19,265	63,534
Net income	280,181	28,255	40,851	1,284	24,536	(19,265)	355,842
Net income attributable to noncontrolling interests	911						911
Net income attributable to Amdocs Limited	\$ 279,270	\$ 28,255	\$ 40,851	\$ 1,284	\$ 24,536	\$ (19,265)	\$ 354,931

Thank you!

 amdocs |  make it amazing

